Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05741164. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
ClinicalTrials.gov study NCT06247449. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT07017673. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT04674306. IPD Sharing: YES. Countries: 1. Publications: 0.
Arsenous Acid for Refractory Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT06678048. IPD Sharing: NO. Countries: 1. Publications: 0.
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
ClinicalTrials.gov study NCT07054242. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
ClinicalTrials.gov study NCT04582955. IPD Sharing: Not stated. Countries: 1. Publications: 0.
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
ClinicalTrials.gov study NCT07178730. IPD Sharing: NO. Countries: 0. Publications: 0.
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05300958. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT06355024. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer
ClinicalTrials.gov study NCT02934828. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT02670109. IPD Sharing: NO. Countries: 1. Publications: 0.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ClinicalTrials.gov study NCT05812807. IPD Sharing: UNDECIDED. Countries: 3. Publications: 0.
Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05686720. IPD Sharing: NO. Countries: 1. Publications: 0.
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05177796. IPD Sharing: Not stated. Countries: 1. Publications: 0.
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT07342283. IPD Sharing: NO. Countries: 0. Publications: 0.
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Brea
ClinicalTrials.gov study NCT02130700. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
ClinicalTrials.gov study NCT05953909. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)
ClinicalTrials.gov study NCT06182306. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
ClinicalTrials.gov study NCT03961698. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.